Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eisai appoints and promotes to manage MGI takeover

This article was originally published in Scrip

Executive Summary

Eisaihas made five appointments and six promotions at its Woodcliff Lake facility in New Jersey and its formulation R&D facility in Research Triangle Park in North Carolina.

Eisaihas made five appointments and six promotions at its Woodcliff Lake facility in New Jersey and its formulation R&D facility in Research Triangle Park in North Carolina.

The company has appointed Rosa Estrella senior counsel to provide legal support to its business development, strategic alliances and global medical and marketing services; Shawn Gallagher senior director of outsourced manufacturing operations; Kevin Chen associate director of biostatistics; Karen Parrish microbiologist IV at the Research Triangle Park facility; and Dr Tushar Patel associate director of scientific evaluation, business development.

Eisai has also promoted Vincent Andrews to associate general counsel; Robert Feeney to senior director, federal government relations; Lawrence Kristoff to associate director, materials management; Rad Mignerey to associate director, incentive compensation; and Mark Schwab to district manager, sales and marketing.

Eisai acquired MGI Pharma in January for $3.9 billion. The new appointments and promotions, which should not have any significant impact on its finances, are partly intended to enable Eisai to operate and manage its new acquisition, the company told Scrip. MGI boosted Eisai's net sales by 11% in its first quarter to ¥195.8 billion ($1.8 billion; ScripOnline, August 1st, 2008).

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC030986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel